Entrada Therapeutics
TRDA
33 hedge funds and large institutions have $386M invested in Entrada Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
28% more capital invested
Capital invested by funds: $302M → $386M (+$84.5M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
0.83% less ownership
Funds ownership: 78.99% → 78.15% (-0.83%)
13% less funds holding
Funds holding: 38 → 33 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.79M |
| 2 |
SG
StepStone Group
La Jolla,
California
|
+$1.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.37M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.21M |
| 5 |
BlackRock
New York
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.71M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.6M |
| 3 |
CA
CHI Advisors
New York
|
-$1.99M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$1.29M |
| 5 |
Millennium Management
New York
|
-$932K |
TRDA Hedge Fund Activity: Q3 2022 in Review
33 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q3 2022, worth a combined $386M — up 28% from $302M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TRDA and 4 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 14 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $6.79M. The largest seller was Wellington Management Group, cutting an estimated $6.71M.
- 33 institutional investors held Entrada Therapeutics (TRDA) as of Q3 2022, down from 38 in Q2 2022.
- Funds reported $386M of Entrada Therapeutics stock for Q3 2022, up 28% quarter-over-quarter.
- 4 funds opened new Entrada Therapeutics positions in Q3 2022 and 9 closed out, a net change of -5 holders.
- The largest Entrada Therapeutics buyer in Q3 2022 was T. Rowe Price Associates, an estimated $6.79M added.
- The largest Entrada Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $6.71M sold.
Based on aggregated 13F filings for Q3 2022.